Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats

Ayse G Kebapcilar, Ayşe Gül Kebapçılar, Tolgay Tuyan İlhan, Tolgay T Ilhan, Duygu Dursunoglu, Duygu Dursunoğlu, Levent Kebapcilar, Levent Kebapçılar, Süleyman Hilmi İpekçi, Suleyman H Ipekci, Suleyman Baldane, Süleyman Baldane, Mustafa Gazi Uçar, Mustafa G Ucar, Cem Onur Kıraç, Cem O Kirac, Kubra Kurt, Kübra Kurt, Çetin Çeli̇k, Cetin Celik
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2017 · vol. 33(12) , pp. 923–927 · doi:10.1080/09513590.2017.1320384 · PMID:28452240 · W2610096835
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

Oral rosuvastatin and intraperitoneal bevacizumab significantly reduced surgically induced endometriotic implants in rats compared to oral progesterone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This study hypothesizes that oral rosuvastatin, oral dienogest and intraperitoneal bevacizumab might improve endometriosis in randomly selected female Wistar albino rats with surgically endometriotic implants. Thirty female Wistar albino rats with surgically endometriotic implants were randomized into three treatment groups: oral rosuvastatin (20 mg kg/day; oral rosuvastatin group 1; n = 10), oral progesterone (dienogest group 2; n = 10) and intraperitoneal bevacizumab (2.5 mg/kg of single intraperitoneal injection of bevacizumab; bevacizumab group 3; n = 10), for 10 days. Post-treatment variables were compared. The oral rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than the oral progesterone group (both, p 0.017). Endometrial thickness values and uterine volume values were more significantly reduced in the oral rosuvastatin group than the oral progesterone group (both, p 0.017). In conclusion, oral rosuvastatin and intraperitoneal injection of bevacizumab may cause more significant regression of surgically endometriotic implants in rats than oral progesterone medications.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Angiogenesis Inhibitors Bevacizumab Endometriosis Hydroxymethylglutaryl-CoA Reductase Inhibitors Nandrolone Rosuvastatin Calcium Angiogenesis Inhibitors Animals Bevacizumab Drug Evaluation, Preclinical Endometriosis Female Hydroxymethylglutaryl-CoA Reductase Inhibitors Nandrolone Nandrolone Rats, Wistar Rosuvastatin Calcium

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Cited by (6)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:31.759405+00:00
License: CC0 · commercial use OK